METOPROLOL TARTRATE INJECTION, USP SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

METOPROLOL TARTRATE

から入手可能:

STRIDES PHARMA CANADA INC

ATCコード:

C07AB02

INN（国際名）:

METOPROLOL

投薬量:

1MG

医薬品形態:

SOLUTION

構図:

METOPROLOL TARTRATE 1MG

投与経路:

INTRAVENOUS

パッケージ内のユニット:

100

処方タイプ:

Prescription

治療領域:

BETA-ADRENERGIC BLOCKING AGENTS

製品概要:

Active ingredient group (AIG) number: 0111923004; AHFS:

認証ステータス:

APPROVED

承認日:

2020-08-13

製品の特徴

_Page 1 of 37 _
PRODUCT MONOGRAPH
PR
METOPROLOL TARTRATE INJECTION, USP
1 mg/mL – 5 mL vial
STERILE SOLUTION FOR INTRAVENOUS INJECTION
ß-Adrenergic Receptor Blocking Agent
Strides Pharma Canada Inc.
1565, Boul. Lionel-Boulet
Varennes, Quebec
Canada, J3X 1P7
Date of Revision:
August 12, 2020
Submission Control No.: 241321
_Page 2 of 37 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
..................................................................................
4
ADVERSE REACTIONS
....................................................................................................
9
DRUG INTERACTIONS
..................................................................................................
11
DOSAGE AND ADMINISTRATION
..............................................................................
17
OVERDOSAGE
................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 20
STORAGE AND STABILITY
..........................................................................................
23
SPECIAL HANDLING INSTRUCTIONS
.......................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 24
PART II: SCIENTIFIC INFORMATION
...............................................................................
25
PHARMACEUTICAL INFORMATION
..........................................................................
25
DETAILED PHARMACOLOGY
....................